$GEGR MARKET DATA FOR REGENERATIVE MEDICINE 202
Post# of 115
(Total Views: 331)
Posted On: 03/22/2021 10:45:38 AM
$GEGR MARKET DATA FOR REGENERATIVE MEDICINE
2020 was an unprecedented year for the field of regenerative medicine and advanced therapies. Not only because of the inevitable impact due to the COVID-19 pandemic, but above all because, despite the consequent economic crisis generated by the global emergency, the sector demonstrated a remarkable resilience in the first half of 2020. Patients continued to benefit from cellular and gene therapies currently on the market and being tested. Investment in the sector has been robust and significant gains have been made by improving market access policy.
"Clinical progress has continued, although with new obstacles caused by the pandemic and its effects," writes Janet Lambert, CEO of Alliance for Regenerative Medicine (ARM), an international advocacy organization dedicated to regenerative drugs and advanced therapies, in the recent report "Innovation in the Time of COVID-19".
2020 was an unprecedented year for the field of regenerative medicine and advanced therapies. Not only because of the inevitable impact due to the COVID-19 pandemic, but above all because, despite the consequent economic crisis generated by the global emergency, the sector demonstrated a remarkable resilience in the first half of 2020. Patients continued to benefit from cellular and gene therapies currently on the market and being tested. Investment in the sector has been robust and significant gains have been made by improving market access policy.
"Clinical progress has continued, although with new obstacles caused by the pandemic and its effects," writes Janet Lambert, CEO of Alliance for Regenerative Medicine (ARM), an international advocacy organization dedicated to regenerative drugs and advanced therapies, in the recent report "Innovation in the Time of COVID-19".
(0)
(0)